Incyte (MEX:INCY) Valuation Rank


MEX:INCY Incyte Corp MEX:INCY
84 GF Score
Price MXN1,676.03
GF Value MXN1,427.31
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Incyte Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Incyte Valuation Rank Related Terms

MEX:INCY
84GF Score
Incyte Corp MEX:INCY
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Incyte (MEX:INCY) Overvalued in 2026?

Based on GuruFocus' analysis, Incyte stock appears to be overvalued. The current stock price of MXN1,676.03 is trading 17.4% above its estimated GF Value™ of MXN1,427.31. GuruFocus considers Incyte to be Modestly Overvalued.

Key valuation signals for MEX:INCY:

  • Valuation Rank:
  • GF Value™: MXN1,427.31 vs. price of MXN1,676.03 (17.4% above fair value)
  • GF Score™: 84/100 with 4 warning signs

No single metric tells the full story. See the MEX:INCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Incyte Business Description

Address 1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
84GF Score

Get the complete analysis for MEX:INCY

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,676.03
Price
MXN1,427.31
GF Value